Suggested region and language based on your location
Your current region and language
GSK Worthing: First UK site with BSI Kitemark™ for Minimized Risk of AMR in antibiotics manufacturing.
“We believe that by taking these steps towards responsible antibiotic manufacturing, we can contribute to getting ahead of AMR.”
A driving cause of AMR is manufacturing waste from the production of antibiotics being released into the environment, for example through wastewater. While GSK had a formalized programme in place to review its internal and manufacturing supply chains to minimize risk of AMR, their achievement of BSI Kitemark certification takes this one step further, independently certifiying GSK’s responsible manufacturing practices and commitment to protecting public health and the environment.
Achieving Kitemark certification involved evaluating the manufacturing processes of seven antibiotic products at the GSK Worthing site. On-site inspection of manufacturing operations was conducted by BSI auditors,including reviews of the wastewater treatment operations, storage areas, and interviews with key site team members. As part of its efforts to combat AMR and positively impact the health of people and the planet, GSK has committed to certification at all its antibiotic manufacturing sites around the world by 2026.
How BSI Kitemark certification at its Worthing manufacturing site is helping GSK to address AMR and achieve its environmental management goals:
Assurance that the antibiotics manufacturing process meets the highest international standard.
Demonstrates its commitment to addressing AMR and minimizing antimicrobial waste in the environment.
Ensures waste streams containing APIs and drug products are suitably controlled during manufacturing.
Helps protect the efficacy of antibiotics in fighting diseases.
Validates compliance with the AMR Industry Alliance’s Antibiotic Manufacturing standard.
BSI Kitemark certification further assures healthcare procurers, investors, and customers.
GSK is playing a leading role in the fight against AMR. Key figures include:
R&D projects targeting pathogens deemed ‘critical’ or ‘urgent’ by WHO and US CDC.
in more than 75 countries worldwide.
in the Access to Medicine Foundation’s AMR Benchmark innovation category.
Pledged to the Fleming Initiative, to develop new AMR interventions.
Years of running the Survey of Antibiotic Resistance, a multinational surveillance programme.
Years of expertise in infectious disease R&D.
Achieving certification through the BSI Kitemark™ for Minimized Risk of AMR Certification addresses a WHO global health threat, assures stakeholders, and helps protect antibiotic efficacy for future generations.
Build trust and confidence with the BSI Kitemark™ for minimized risk of antimicrobial resistance.
